Publications by authors named "Golda Gross"
Article Synopsis
- - CD19 CAR-T cells have shown long-lasting remission in patients with hard-to-treat B-cell cancers, but many eventually relapse, prompting research into ways to enhance their effectiveness.
- - A study found that CAR-T cells leading to complete responses had higher mitochondrial function, suggesting that boosting cellular metabolism could improve their efficacy in treating leukemia.
- - By switching the growth medium from glucose to galactose, researchers increased mitochondrial activity in CAR-T cells, leading to better performance in lab tests and improved leukemia-free survival in mouse models compared to traditional glucose-based methods.
CD19 CAR-T cells have led to durable remissions in patients with refractory B-cell malignancies; nevertheless, most patients eventually relapse in the long term. Many interventions aimed at improving current products have been reported, with a subset of them focusing on a direct or indirect link to the metabolic state of the CAR-T cells. We assessed clinical products from an ongoing clinical trial utilizing CD19-28z CAR-T cells from patients with acute lymphoblastic leukemia.
View Article and Find Full Text PDF